S&K Therapeutics owns an AI-based drug development platform that allows us to discover new molecular entities effectively. Furthermore, based on extensive research experience on TLRs (Toll-like receptors), S&K therapeutics is establishing new drug development pipelines for autoimmune diseases, inflammatory diseases, and viral diseases.
S&K Therapeutics is focusing its core capabilities on developing new small molecule drugs to meet the unmet medical needs, and aims to develop new medicine for lupus, RA, psoriasis, Alzheimer's, and diabetes.
S&K is a new drug development platform that mainly focuses on the lead compound discovery using artificial intelligence and computational techniques. S&K implements the innovative technology that can reduce the total duration of drug development from 10 years to 5 years.
The TLR (Toll-like receptor) is one of the major factors in the pathogenesis of lupus. TLR signaling pathway plays a crucial role in the activation of innate immune responses, which is the first line of defense against external/foreign substances. TLR immediately responds to the invading pathogenic substances and secretes various cytokines to help the development of acquired immunity. However, if TLR signaling is over-activated, it can cause autoimmune or inflammatory diseases such as systemic lupus erythematosus or rheumatoid arthritis, which can be treated by directly blocking the signal transduction of the TLR.
Lupus is a disease that causes inflammatory reactions due to autoimmunity, which has various symptoms such as skin rash, photosensitivity, arthritis, canker sores, nephritis, hematocytopenia, angitis and hydrohymenitis.
